Saxenda for weight loss: what the liraglutide data actually shows

What did @weight_lost_store actually say?

Here's the awkward truth: they didn't really say anything. The transcript from this 26.8K-view video is entirely song lyrics, something about "sweetest addiction" and "strongest inspiration." There is no spoken medical claim, no dosing advice, no before-and-after narration. The only substantive content appears in the caption, which describes Saxenda as "an injectable medicine used for adults with excess weight who may also have weight-related medical problems or obesity and children aged 12-17." That's it. The video is effectively a branded aesthetic post with a drug name attached to it.

This matters because the caption's phrasing is lifted almost verbatim from Saxenda's prescribing label and FDA approval summary. That's not analysis. That's copy-paste with heart emojis.

Does the science back this up?

The caption's core claim, that Saxenda is approved for adults with obesity or weight-related conditions and adolescents aged 12-17, is accurate. The FDA first approved liraglutide 3mg (Saxenda) for chronic weight management in adults in 2014, then extended that approval to adolescents in 2020. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, New England Journal of Medicine) showed adults on liraglutide 3mg lost an average of 8.4kg versus 2.8kg on placebo over 56 weeks. For adolescents, the SCALE Kids trial (Kelly et al., 2020, NEJM) found a reduction in BMI standard deviation score of 0.22 in the liraglutide group versus an increase of 0.22 in placebo. Statistically significant. Clinically modest, depending on your threshold.

So yes, the drug exists, it's approved for those populations, and there is real trial data behind it. The caption gets the regulatory facts right.

What did they get wrong (or right)?

The caption is technically accurate but dangerously incomplete. Describing Saxenda purely as an injectable for people with "excess weight" with no mention of contraindications, side effects, or the requirement for a prescription gives followers a sales-brochure version of a serious pharmaceutical. Saxenda carries an FDA boxed warning for thyroid C-cell tumors based on rodent data. It's contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. Common side effects, nausea, vomiting, diarrhea, affect a substantial portion of users in the first weeks of treatment.

The account name, @weight_lost_store, suggests a commercial motive. Pairing a drug name with hashtags like "semagl" (shorthand for semaglutide, a different drug entirely) and misspelling the drug as "sexenda" in the hashtags signals this is marketing content, not patient education. That conflation of semaglutide and liraglutide is not a minor typo. They are different molecules with different mechanisms, different dosing intervals, and different approval histories.

What should you actually know?

Saxenda (liraglutide 3mg) and semaglutide-based drugs like Wegovy are both GLP-1 receptor agonists but they are not interchangeable. Liraglutide requires daily injections. Semaglutide (Wegovy) is weekly. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced roughly 14.9% body weight loss versus about 8% seen with liraglutide in comparable populations. That gap is clinically relevant if you're weighing options with a prescriber.

For adolescents specifically, the 2020 FDA expansion for Saxenda applies to teens 12 and older with an initial BMI at or above the 95th percentile. It is not a general pediatric weight loss tool and should not be treated as one.

• Saxenda requires a valid prescription from a licensed provider who has reviewed your medical history.
• The thyroid tumor warning is a boxed warning, the FDA's strongest safety label.
• Mixing up liraglutide and semaglutide when discussing treatment options with patients or on public platforms can cause real confusion about what someone is actually taking.
• No GLP-1 medication is a permanent fix. Weight regain after discontinuation is well-documented (Wilding et al., 2022, Diabetes, Obesity and Metabolism).